Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Amit Sanyal, MD: A Clinician’s Perspective

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement




Sep
23
Today In Oncology
Dual Oral Regimen Shows Encouraging Activity in KRAS G12C–Mutated Metastatic Colorectal Cancer
BRAF Class Alterations in NSCLC Have Different Characteristics, Outcomes, and Co-Mutations, Research Shows
AACR Releases Annual Cancer Progress Report
Plant-Based Diet Linked to Lower Risk of Prostate Cancer Progression on Active Surveillance
KEYNOTE-826 Long-Term Outcomes With Pembrolizumab Plus Chemotherapy in Advanced Cervical Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo